Published in Antimicrob Agents Chemother on September 01, 1984
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother (1987) 7.33
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Antifungal susceptibility tests. Antimicrob Agents Chemother (1987) 4.76
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1997) 3.01
Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother (1990) 2.37
Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. J Clin Microbiol (1992) 2.12
Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol (1998) 1.89
pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother (1989) 1.60
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1993) 1.58
Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother (1988) 1.55
Effect of buffers on testing of Candida species susceptibility to flucytosine. J Clin Microbiol (1987) 1.44
Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J Clin Microbiol (1986) 1.30
In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother (1992) 1.09
Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media. J Clin Microbiol (1993) 1.03
Specific induction of fibronectin binding activity by hemoglobin in Candida albicans grown in defined media. Infect Immun (1996) 0.83
Hydrogen ion buffers for biological research. Biochemistry (1966) 30.95
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy (1975) 3.51
Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother (1983) 3.06
THE STABILITY CONSTANTS OF METAL-ADENINE NUCLEOTIDE COMPLEXES. Biochemistry (1964) 3.04
Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole. J Infect Dis (1975) 1.50
Rapid microbiological assay for 5-fluorocytosine. Br Med J (1973) 1.47
Comparative effects of acidosis induced by acid infusion and carbon dioxide accumulation. Am J Physiol (1960) 1.38
Disk agar diffusion susceptibility testing of yeasts. Antimicrob Agents Chemother (1978) 1.35
Stability of four antifungal antimicrobics in vitro. J Infect Dis (1978) 1.17
Influence of tris on contracile responses of isolated rat aorta and portal vein. Am J Physiol (1978) 1.01
Adverse effects of Tris. HEPES and MOPS buffers on contractile responses of arterial and venous smooth muscle induced by prostaglandins. Prostaglandins Med (1980) 1.00
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother (1995) 4.92
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol (1996) 2.44
Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med (1994) 2.44
Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother (1990) 2.37
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med (1993) 1.83
Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn Microbiol Infect Dis (1994) 1.73
Susceptibility of Candida albicans to flucytosine when tested in different formulations of yeast nitrogen base broth. Diagn Microbiol Infect Dis (1986) 1.68
pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother (1989) 1.60
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1993) 1.58
Treatment of fungal meningitis with miconazole. Arch Intern Med (1977) 1.57
High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med (1984) 1.51
Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions. Infect Immun (1987) 1.48
Coccidioidomycosis at a university health service. Am Rev Respir Dis (1985) 1.48
Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med (1990) 1.43
Comparison of immunodiffusion techniques with standard complement fixation assay for quantitation of coccidioidal antibodies. J Clin Microbiol (1983) 1.43
Gynecomastia with ketoconazole. Antimicrob Agents Chemother (1981) 1.42
Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature. Medicine (Baltimore) (1986) 1.36
Coccidioidomycosis in renal replacement therapy. Arch Intern Med (1982) 1.36
Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother (1987) 1.34
Deep infections from Petriellidium boydii treated with miconazole. JAMA (1979) 1.32
Humoral antibody responses to specific antigens of Coccidioides immitis. J Infect Dis (1986) 1.31
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med (1995) 1.29
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob Agents Chemother (1996) 1.26
Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats. Antimicrob Agents Chemother (1984) 1.25
Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole. Rev Infect Dis (1981) 1.23
Coccidioidomycosis: clinical update. Rev Infect Dis (1990) 1.20
Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) (1990) 1.19
Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect Immun (1998) 1.18
Cloning and sequence analysis of the cDNA for a protein from Coccidioides immitis with immunogenic potential. Biochem Biophys Res Commun (1996) 1.16
Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis. J Infect Dis (1996) 1.15
Genetic transformation of Coccidioides immitis facilitated by Agrobacterium tumefaciens. J Infect Dis (2000) 1.13
An immunoreactive apoglycoprotein purified from Coccidioides immitis. Infect Immun (1991) 1.13
Antigenemia in primary coccidioidomycosis. Am J Trop Med Hyg (1984) 1.10
Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother (1983) 1.09
Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.09
Chemotaxigenic activity of extracts from the mycelial and spherule phases of Coccidioides immitis for human polymorphonuclear leukocytes. Infect Immun (1978) 1.07
Symptoms and routine laboratory abnormalities associated with coccidioidomycosis. West J Med (1988) 1.07
Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis (1990) 1.06
Coccidioidomycosis among visitors to a Coccidioides immitis-endemic area: an outbreak in a military reserve unit. J Infect Dis (1995) 1.05
Paracoccidioidomycosis (South American blastomycosis): treatment with miconazole. Am J Trop Med Hyg (1978) 1.04
Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infect Immun (1999) 1.04
Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal. J Clin Microbiol (1997) 1.03
Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species. Diagn Microbiol Infect Dis (1994) 1.01
Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis. J Infect Dis (1996) 1.01
Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results. Chest (1984) 1.00
The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis (1993) 1.00
The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice. Infect Immun (2000) 0.99
Coccidioidomycosis. Eur J Clin Microbiol Infect Dis (1989) 0.97
Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole. Am J Med (1978) 0.95
Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. Chest (1988) 0.95
Leukocyte effects on the dimorphism of Coccidioides immitis. J Infect Dis (1982) 0.93
Human polymorphonuclear-leukocyte inhibition of incorporation of chitin precursors into mycelia of Coccidioides immitis. J Infect Dis (1984) 0.92
Ketoconazole in the treatment of coccidioidomycosis. Drugs (1983) 0.92
Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis. Infect Dis Clin North Am (1988) 0.89
Ketoconazole treatment of coccidioidal meningitis. Ann N Y Acad Sci (1988) 0.89
Coccidioidomycosis complicating solid organ transplantation. Semin Respir Infect (2001) 0.88
Amphotericin B-induced myelopathy. Arch Intern Med (1980) 0.87
Production of a murine monoclonal antibody that recognizes an epitope specific to Coccidioides immitis antigen 2. Infect Immun (1993) 0.86
Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis (1991) 0.86
Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med (1990) 0.86
Coccidioides immitis infections in bones and joints. Clin Orthop Relat Res (1986) 0.85
Enzyme-linked immunosorbent assay for antigens of Coccidioides immitis: human sera interference corrected by acidification-heat extraction. J Lab Clin Med (1988) 0.85
Inhibition of different phases of Coccidioides immitis by human neutrophils or hydrogen peroxide. J Infect Dis (1986) 0.85
Dendritic cells pulsed with Coccidioides immitis lysate induce antigen-specific naive T cell activation. J Infect Dis (2001) 0.85
Complement activation by Coccidioides immitis: in vitro and clinical studies. Infect Immun (1980) 0.84
Ketoconazole therapy for fungal urinary tract infections. J Urol (1983) 0.84
Killing of Coccidioides immitis by human peripheral blood mononuclear cells. Infect Immun (1992) 0.84
Itraconazole treatment of experimental systemic candidiasis in male rats. J Med Vet Mycol (1987) 0.83
Fungal endocarditis: need for guidelines in evaluating therapy. Experience with two patients previously reported. J Thorac Cardiovasc Surg (1977) 0.83
Tumor necrosis factor-alpha and interleukin-1 beta in cerebrospinal fluid of patients with coccidioidal meningitis during therapy with fluconazole. National Institute of Allergy and Infectious Diseases Mycoses Study Group. J Infect Dis (1995) 0.83
Neutrophil killing of single microorganisms as measured by a new method. Diagn Microbiol Infect Dis (1989) 0.83
Cavitary coccidioidomycosis with fungus ball formation. Diagnosis by fiberoptic bronchoscopy with coexistence of hyphae and spherules. Chest (1994) 0.82
Interaction of human peripheral blood mononuclear cells with Coccidioides immitis arthroconidia. Cell Immunol (1991) 0.81
Proline-rich vaccine candidate antigen of Coccidioides immitis: conservation among isolates and differential expression with spherule maturation. J Infect Dis (1999) 0.81
Coccidioidal peritonitis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis (1988) 0.81
Detecting serum antibodies to a purified recombinant proline-rich antigen of Coccidioides immitis in patients with coccidioidomycosis. Clin Infect Dis (1998) 0.80
Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med (1994) 0.80
The incidence and implications of coccidioidouria. Am Rev Respir Dis (1982) 0.80
Analysis of autoantibodies to T-cell receptors among HIV-infected individuals: epitope analysis and time course. Clin Immunol Immunopathol (1997) 0.79
T-lymphocyte predominance in lesions of canine coccidioidomycosis. Vet Pathol (2010) 0.77
Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis (1995) 0.77
Quantitative pathology of coccidioidomycosis in acquired immunodeficiency syndrome. Hum Pathol (1988) 0.76